Loading
Molecular oncologist known for mutant p53 research, appointed Scientific Director of Rome's Regina Elena National Cancer Institute in 2026.
Giovanni Blandino was confirmed as Scientific Director of the IRCCS Regina Elena National Cancer Institute (IRE), part of the IFO group in Rome, in May 2026. He leads the institute's Translational Oncology Research unit, where his laboratory studies gain-of-function mutant p53, its effects on tumour metabolism and non-coding RNAs, and strategies to target it therapeutically. His appointment is announced on the IFO website.
| Title | Journal | Year |
|---|---|---|
| Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth | Nature Communications | 2023 |
| Targeting mutant p53 in cancer: the latest insights | Journal of Experimental & Clinical Cancer Research | 2019 |
Shares Journal of experimental & clinical cancer research and the tags leadership, clinician-scientist, breast cancer.
Shares Triple-negative breast cancer (TNBC) and the tags leadership, clinician-scientist, breast cancer.
Shares Journal of experimental & clinical cancer research and the tags leadership, clinician-scientist.
Shares Journal of experimental & clinical cancer research and the tags leadership, clinician-scientist.
Shares Triple-negative breast cancer (TNBC) and the tags leadership, clinician-scientist, breast cancer.
Shares the tags leadership, clinician-scientist, breast cancer.
Shares Triple-negative breast cancer (TNBC) and the tags leadership, clinician-scientist, breast cancer.
Shares Triple-negative breast cancer (TNBC) and the tags leadership, clinician-scientist, breast cancer.